Aralez Pharma Stock Analysis (NASDAQ:ARLZ)

Add to My Stocks
$4.5 $0.02 (0.44%) ARLZ stock closing price Feb 17, 2017 (Closing)
Watch Robo Advisor Video of ARLZ Stock Analysis
Aralez Pharma
Updated on : Feb 17, 2017
previous close
ARLZ 4.5 (0%)
S&P 500 2351.2 (0%)
Closing Price On: Feb 17, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q3
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
-1.3%
Operating Profit
Operating Margin:
-219.9%
Sector Average:
-1.3%
5 Quarter Net Profit
Net Margins
2016-Q3
%
LTM Margin
Debt/Equity Ratio
Debt:
74.5M
Debt/Equity Ratio:
 0.5
Compared to the industry
Cash Flow
Operating cash flow:
-$10.9M
Net Income:
-$20.6M
PROS      CONS
Recent Growth
Long Term Growth
Operating Margins
Net Margins
High Debt Burden
ROIC
ROE
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
ARLZ PS :
7.3
Industry PS :
4.8
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-93.3%
Return on Equity:
-77.7%
Free Cash Flow Margin:
-90.2%
Double Tap To Exit Full Screen
0:00
/

Aralez Pharma Analysis Video

143 5 2

View Aralez Pharma stock analysis video. This is our ARLZ analyst opinion covering the buy and sell arguments for ARLZ stock.

Aralez Pharmaceuticals Inc Stock Rating (1.9/5)

Our Aralez Pharma stock opinion is based on fundamentals of the company. This Aralez Pharma stock analysis is based on latest Q3 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy ARLZ stock?

  • Aralez Pharma's revenue growth came in at 134.2% in 2016 Q3.

Should you sell ARLZ stock?

  • The company saw an average annual sales decline of in sales over the last 5 years.
  • Aralez Pharma reported an average operating margin of -219.9% over the Last Twelve Months (LTM).
  • Over the last 12 months, Aralez Pharma had an average Net loss of -211.7%.
  • Aralez Pharma is debt laden and has a high debt/equity ratio of  0.5.
  • The lack of profits renders the PE ratio useless for ARLZ stock.
  • The company has a negative Return on Invested Capital of -93.3%, which is a red flag.
  • Aralez Pharma has a negative return on equity of -77.7%. This indicates that the firm is inefficient at generating profits.
  • The company has a negative free cash flow margin of -90.2%.

Comments on this video and Aralez Pharma stock